Product Details

Quantifying Risk in Clinical Trials

Investigative site personnel have little or no information about the general risks of participating in clinical trials. Yet communicating this information could positively influence patient recruitment.

A recent CenterWatch analysis finds that the incidence of deaths during government- and industry-sponsored clinical trials is rare. One adverse event per study subject is typically reported on NDAs approved by FDA.

A Market Receives EDC

Within two years, the market for EDC technologies has doubled to nearly $130 million. Sponsors are pushing EDC out of pilot usage and into their major clinical projects.

Market leaders Phase Forward and CB Technologies are driving consolidation and joint venture activity in order to offer sponsors more integrated e-process solutions. Ultimately, these solutions will change that way that investigative sites, CROs and sponsors manage and conduct clinical trials.

Also in this issue:

• CentreStage Europe: The Groupe MAPI Builds DataBase of French Investigators
• Eye On: Type I Diabetes